{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:13:45Z","timestamp":1789017225199,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.brachy.2021.12.004","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:26:18Z","timestamp":1643847978000},"page":"308-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-814X","authenticated-orcid":false,"given":"Hathal","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Hermani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Hanitzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0444-5280","authenticated-orcid":false,"given":"Attila","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-297X","authenticated-orcid":false,"given":"Michael","family":"Pinkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2021.12.004_bib0001","series-title":"World Cancer Report 2014","author":"Stewart","year":"2014"},{"key":"10.1016\/j.brachy.2021.12.004_bib0002","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.brachy.2021.12.004_bib0003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.brachy.2021.12.004_bib0004","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.brachy.2021.05.010","article-title":"PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: a phase 2 randomized pilot study","volume":"20","author":"Reynaud","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0005","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","article-title":"Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement","volume":"20","author":"King","year":"2021","journal-title":"Brachytherapy"},{"issue":"Suppl 1","key":"10.1016\/j.brachy.2021.12.004_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2021.12.004_bib0007","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.brachy.2021.04.004","article-title":"Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer","volume":"20","author":"Goy","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.brachy.2021.01.001","article-title":"Ultra-long-term toxicity of prostate brachytherapy","volume":"20","author":"Thompson","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0167-8140(00)00306-6","article-title":"ESTRO\/EAU\/EORTC recommendations on permanent seed implantation for localized prostate cancer","volume":"57","author":"Ash","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.21037\/tau.2019.10.01","article-title":"Epidemiology and treatment modalities for the management of benign prostatic hyperplasia","volume":"8","author":"Lokeshwar","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0011","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"issue":"Suppl 9","key":"10.1016\/j.brachy.2021.12.004_bib0012","first-page":"S3","article-title":"Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia","volume":"6","author":"Lepor","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00120-015-3983-0","article-title":"S2e guideline of the German urologists: instrumental treatment of benign prostatic hyperplasia","volume":"55","author":"Bschleipfer","year":"2016","journal-title":"Urologe A"},{"key":"10.1016\/j.brachy.2021.12.004_bib0014","series-title":"EAU Guidelines Edn presented at the EAU Annual Congress Amsterdam 2020","article-title":"EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), inclusive benign prostatic obstruchtion (BPO)","year":"2020"},{"key":"10.1016\/j.brachy.2021.12.004_bib0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2021.12.004_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","article-title":"Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO\/EAU\/EORTC recommendations on prostate brachytherapy","volume":"83","author":"Salembier","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0017","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.12.004_bib0018","first-page":"99","article-title":"Successful intra-arterial embolization of bleeding carcinoma of the prostate (author's transl)","volume":"16","author":"Bischoff","year":"1977","journal-title":"Urologe A"},{"key":"10.1016\/j.brachy.2021.12.004_bib0019","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jvir.2017.10.013","article-title":"Safety and efficacy of prostatic artery chemoembolization for prostate cancer-initial experience","volume":"29","author":"Pisco","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.juro.2016.08.100","article-title":"Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression","volume":"197","author":"Shim","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0021","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.urology.2015.04.037","article-title":"Prostatic arterial embolization vs open prostatectomy: a 1-year matched-pair analysis of functional outcomes and morbidities","volume":"86","author":"Russo","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2021.12.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2016.08.004","article-title":"Meta-analysis of prostatic artery embolization for benign prostatic hyperplasia","volume":"27","author":"Uflacker","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0023","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jvir.2016.04.001","article-title":"Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients","volume":"27","author":"Pisco","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0024","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1148\/radiol.2016152292","article-title":"Predictors of clinical outcome after prostate artery embolization with spherical and nonspherical polyvinyl alcohol particles in patients with benign prostatic hyperplasia","volume":"281","author":"Bilhim","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.brachy.2021.12.004_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urology.2018.07.012","article-title":"Prostate artery embolization for lower urinary tract symptoms secondary to benign prostatic hyperplasia: results from a prospective fda-approved investigational device exemption study","volume":"120","author":"Salem","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2021.12.004_bib0026","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s00270-013-0680-5","article-title":"Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it","volume":"36","author":"Carnevale","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0027","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00345-015-1665-6","article-title":"Early results and complications of prostatic arterial embolization for benign prostatic hyperplasia","volume":"34","author":"Lebdai","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0028","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bju.13147","article-title":"Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates","volume":"117","author":"Wang","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2021.12.004_bib0029","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.prnil.2020.04.001","article-title":"Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia","volume":"8","author":"Radwan","year":"2020","journal-title":"Prostate Int"},{"key":"10.1016\/j.brachy.2021.12.004_bib0030","first-page":"131","article-title":"Prostatic artery embolization is able to improve the prostatic urethral angle in patients with lower urinary tract symptoms","volume":"3","author":"Bernard","year":"2020","journal-title":"Urol Res Ther J"},{"key":"10.1016\/j.brachy.2021.12.004_bib0031","first-page":"132","article-title":"Impact of prostate artery embolization on irritative lower urinary tract storage symptoms: a retrospective analysis in 176 men","volume":"3","author":"Bernard","year":"2020","journal-title":"Urol Res Ther J"},{"key":"10.1016\/j.brachy.2021.12.004_bib0032","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1148\/radiol.13122803","article-title":"Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate\u2013a prospective, randomized, and controlled clinical trial","volume":"270","author":"Gao","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.brachy.2021.12.004_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00270-015-1202-4","article-title":"Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis","volume":"39","author":"Carnevale","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0034","doi-asserted-by":"crossref","first-page":"k2338","DOI":"10.1136\/bmj.k2338","article-title":"Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial","volume":"361","author":"Abt","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.brachy.2021.12.004_bib0035","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/j.amjmed.2019.04.037","article-title":"Prostate artery embolization in patients with acute urinary retention","volume":"132","author":"Kenny","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.brachy.2021.12.004_bib0036","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jvir.2018.05.012","article-title":"Prostate artery embolization in patients with prostate volumes of 80 ml or more: a single-institution retrospective experience of 93 patients","volume":"29","author":"Bhatia","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0037","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1007\/s00330-015-4177-2","article-title":"Can prostatic arterial embolisation (PAE) reduce the volume of the peripheral zone? MRI evaluation of zonal anatomy and infarction after PAE","volume":"26","author":"Lin","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0038","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12894-020-00726-y","article-title":"Prostate artery embolization has long term efficacy for treatment of severe lower urinary tract symptoms from giant prostatic hyperplasia","volume":"20","author":"Somwaru","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0039","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.brachy.2011.01.014","article-title":"American college of radiology appropriateness criteria permanent source brachytherapy for prostate cancer","volume":"10","author":"Frank","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0041","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2004.09.004","article-title":"GEC\/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer","volume":"74","author":"Kovacs","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0042","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2010.08.045","article-title":"American society for radiation oncology (ASTRO) and American college of radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer","volume":"79","author":"Rosenthal","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2021.12.004_bib0043","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2015.11.022","article-title":"Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer","volume":"118","author":"Gaudet","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0044","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0045","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.brachy.2021.12.004_bib0046","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2016.11.017","article-title":"American brachytherapy society task group report: use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review","volume":"16","author":"Keyes","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0047","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brachy.2020.08.023","article-title":"Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: a propensity score-matched analysis","volume":"20","author":"Sutani","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2021.12.004_bib0048","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00066-006-1529-5","article-title":"Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer","volume":"182","author":"Pinkawa","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0049","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.radonc.2007.07.014","article-title":"Evaluation of source displacement and dose\u2013volume changes after permanent prostate brachytherapy with stranded seeds","volume":"84","author":"Pinkawa","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0050","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cam4.1443","article-title":"Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer","volume":"7","author":"Nishimura","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.brachy.2021.12.004_bib0051","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2010.02.010","article-title":"Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer","volume":"96","author":"Pinkawa","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0052","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.ju.0000152698.20487.0e","article-title":"Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy","volume":"173","author":"Kollmeier","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2021.12.004_bib0053","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.juro.2013.05.010","article-title":"Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters","volume":"190","author":"Mock","year":"2013","journal-title":"J Urol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121005419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472121005419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:17:19Z","timestamp":1761531439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472121005419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1538472121005419"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2021.12.004","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}